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ABSTRACT: 
 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that results in 
loss of the upper and lower motor neurons from motor cortex, brainstem and spinal cord. Whilst 
the majority of cases are sporadic, around 10% show familial inheritance. ALS is usually inherited 
in an autosomal dominant manner, though autosomal recessive and X-linked inheritance do 
occur. To date, 24 of the genes at 26 loci have been identified; these include loci linked to ALS as 
well as to FTD-ALS, where family pedigrees contain individuals with frontotemporal dementia 
with/without ALS. The most commonly established genetic causes of FALS to date are the 
presence of a hexanucleotide repeat expansion in the C9ORF72 gene (39.3% FALS) and 
mutation of SOD1, TARDBP and FUS, with frequencies of 12-23.5%, 5% and 4.1% respectively. 
However, with the increasing use of next generation sequencing of small family pedigrees, this 
has led to an increasing number of genes associated with ALS. This review provides a 
comprehensive review on the genetics of ALS and an update of the pathogenic mechanisms 
associated with these genes. Commonly implicated pathways have been established, including 
RNA processing, the protein degradation pathways of autophagy and ubiquitin-proteasome-
system as well as protein trafficking and cytoskeletal function. Elucidating the role genetics plays 
in both FALS and SALS is essential for understanding the subsequent cellular dysregulation that 
leads to motor neuron loss, in order to develop future effective therapeutic strategies.   
 
KEYWORDS: 
Genetics, ALS, C9ORF72, TDP-43, RNA processing, autophagy 
RUNNING HEADER: 
Genetics of ALS  
3 
 
INTRODUCTION 
 
Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder with an incidence of 2-
3 per 100,000 and a lifetime risk of 1 per 400 individuals1. Usually with an adult onset, initial 
clinical symptoms such as loss of dexterity in the fingers or a mild limp in limb onset ALS, or 
slurring of speech in bulbar onset ALS, are caused by loss of the upper motor neurones in the 
motor cortex and brainstem and lower motor neurones in the spinal cord. Overtime, the 
progressive nature of the disease is associated with further muscle wasting, weight loss, 
fasciculations and eventually death due to respiratory failure, 32 months following symptom 
onset. During disease progression, cognitive impairment may develop in up to 40% of patients 
and approximately 5% will go on to develop frontotemporal dementia (FTD). 
 
Whilst the majority of cases are sporadic (SALS) with no familial history of disease, around 10% 
of cases are familial (FALS) and are clinically indistinguishable from SALS cases. Generally, in 
adult onset ALS, the disease is inherited as an autosomal dominant (AD) trait, though rare cases 
of juvenile ALS are more commonly associated with autosomal recessive (AR) inheritance. 
However, there are also instances of AR inheritance of AD genes in specific populations (SOD1 
in Scandinavia and FUS in Cape Verde). In addition, there is evidence of reduced penetrance of 
disease associated mutations (including p.I114T SOD1 and G4C2 C9ORF72) as well as 
oligogenic inheritance2, illustrating that ALS is a highly complex genetic disorder. 
 
The first genetic cause of ALS was identified in 1993 through linkage analysis to the Chr21 
marker DS21S223. Subsequent analysis of the nearby gene, SOD1, identified multiple 
pathogenic mutations in these FALS families. Over the following 16 years, linkage analysis and 
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candidate gene sequencing of ALS families have identified further genes associated with 
autosomal dominant or autosomal recessive ALS and one instance of X-linked inheritance (Table 
1). With the advent of next generation sequencing (NGS), whole exome sequencing (WES) has 
allowed an exponential increase in the identification of disease associated genes (Figure 1). 
Following the first use of WES to identify that the VCP gene was associated with disease, WES 
has been used on many FALS samples and assisted in identifying seven further genes in the last 
three years.  
 
To date, over 22 ALS and 4 ALS+FTD (FTDALS) loci have been established, with the causative 
genes identified in the majority of cases. This review will firstly summarise the current insights 
that have been gained from the four most common causes of FALS: SOD1, TARDBP, FUS and 
C9ORF72. These genes have highlighted the roles of oxidative stress and RNA processing as 
contributory pathogenic mechanisms in ALS. In addition, rarer genetic variants have implicated 
additional biological pathways such as the ubiquitin-proteasome system (UPS), protein trafficking 
and impaired cytoskeletal function.  
 
[Please note, for the purposes of this review, we have used the numbering of loci as described in 
the Online Mendelian Inheritance in Man (OMIM) Phenotypic Series for ALS (PS105400) and 
FTDALS (PS105550).] 
 
ALS1: Cu-Zn Superoxide Dismutase (SOD1) 
 
Mutation of Cu-Zn superoxide dismutase 1 (SOD1) was the first described genetic cause for 
familial ALS3. The majority of SOD1 mutations are AD, with a highly penetrant pattern of 
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inheritance, and are primarily associated with limb onset ALS. An exception to this rule is the 
D90A mutation, predominantly found in Scandinavian populations, where it is inherited in an AR 
manner. Frequency of SOD1 mutations varies depending on populations, from 23.5% in 
Scandinavia to 12% in Germany; mutations have also been identified in apparently sporadic 
cases4. The ALSoD database (http://alsod.iop.kcl.ac.uk)5 reports that there are 183 mutations in 
SOD1 associated with disease (accessed Nov 2015), the majority of which are point mutations. 
Given that SOD1 encodes a 153 amino acid protein, this number is remarkable, with the 
mutations distributed throughout the gene and impacting upon a variety of domains within the 
protein. This is in contrast to some of the other ALS-associated mutations, which are more often 
located within a particular motif of the protein product, particularly as it is unclear whether all of 
the reported SOD1 “mutations” are indeed pathogenic6,7.  
 
The multiple mutations throughout the protein have also resulted in challenges determining how 
they are responsible for the disease phenotype. SOD1 is a ubiquitously expressed antioxidant 
protein, which catalyses free radical superoxide to hydrogen peroxide and oxygen. As the 
majority of mutant proteins retain this enzymatic function, the pathogenicity is proposed to act 
through a toxic gain of function, although the precise nature of this toxicity remains to be 
determined. Many mutually compatible pathogenic mechanisms have been proposed including 
oxidative stress, excitotoxicity, protein aggregation, neuroinflammation, apoptosis, mitochondrial 
dysfunction, axonal transport dysregulation, endoplasmic reticulum (ER) stress8. Mutant SOD1 
proteins (mtSOD1) show variable states of metallation and disulphide bond formation, which 
leads to the ability of the demetalled and unfolded apoform to enter the intermembrane space of 
the mitochondrion thereby causing mitochondrial dysfunction9. In addition, demetallation leads to 
increased instability and mtSOD1 shows a higher aggregation propensity than wild type SOD1 
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(wtSOD1). More recently, mtSOD1, along with misfolded wtSOD1 has been shown to move from 
cell to cell and initiate a prion-like seeded aggregation of SOD110,11. Whilst initial work 
demonstrated the propagation of misfolded protein in cell culture models, spinal homogenates 
from paralysed mutant G93A SOD1 mice injected into 6mth old G85R-SOD1:YFP mice (who 
don’t usually get disease till 20mths) produced a progressive motor neuron disease within 
3mths12. 
 
Normally, misfolded proteins are removed from the cell via the UPS. However in SOD1-ALS, and 
also in SALS, the UPS has been shown to be impaired13,14. In addition, mahogunin ring finger 1, 
an E3 ubiquitin ligase, which catalyses monoubiquitination of proteins and marks them for 
degradation via a UPS-independent mechanism, has been shown to be decreased in the G93A 
mouse model. Interestingly, however, overexpression of this protein reduced SOD1 toxicity by 
suppressing the aggregation of SOD1. Thus, therapeutic strategies for ALS include increasing 
clearance of misfolded SOD1 and the heat-shock protein inducer, arimoclomol, is one such drug 
currently under investigation15.  
 
Whilst initially oxidative stress was thought to be one of the primary mechanisms of mutant 
SOD1, the continued research on SOD1 pathogenic mechanisms has implicated UPS, protein 
aggregation and degradation, as well as other aspects of protein trafficking. These pathways are 
also implicated by the discovery of additional FALS genes (see “Protein Trafficking and 
Degradation Related Genes”).  
 
ALS10: TAR DNA Binding Protein (TARDBP) 
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The transactive response DNA-binding protein 43 (TDP-43) is encoded by TARDBP gene on 
chr1p36.2216. TARDBP is responsible for 4-5% of FALS and nearly 1% of SALS17. Mutations in 
TARDBP are inherited in an AD manner and are associated with a classic ALS clinical 
phenotype. TARDBP encodes several isoforms of which TDP-43 is considered the most 
prevalent. TDP-43 is a heterogeneous nuclear ribonucleoprotein (hnRNP) with a nuclear 
localisation signal (NLS) and nuclear export signal (NES) which allows shuttling of the protein 
between the nucleus and cytoplasm. The TDP-43 protein contains three further domains, two 
RNA recognition motifs (RRM1 and RRM2), involved in RNA and DNA binding, and a glycine rich 
domain (GRD), which is essential for interactions with other proteins and is the location of the 
majority of mutations18,19. 
 
TDP-43 was initially identified as a transcription repressor that binds to TAR DNA in human 
immunodeficiency virus-1 (HIV-1)20. Subsequently, TDP-43 has been shown to play a role in RNA 
metabolism, including: RNA transcription, alternative splicing, pre-miRNA processing, RNA 
transport and mRNA stability21. TDP-43 has the ability to auto-regulate its own gene expression 
by binding to the 3’ untranslated region (3’UTR) of its mRNA, leading to instability and decay22. 
TDP-43 also binds to UG rich sequences in multiple mRNA sequences to regulate splicing23-25. In 
addition, a novel function has recently been described, with TDP-43 able to repress the splicing of 
non-conserved exons known as cryptic exons26. Removal of TDP-43 allowed these cryptic exons 
to be incorporated into mRNA sequences, which subsequently disrupted translation and induced 
nonsense mediated decay (NMD). Finally, TDP-43 is also known to be a component of stress 
granules (SGs), although it is unclear whether this role contributes to neurodegeneration27. 
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TDP-43 is a prominent protein in the characteristic ubiquitinated cytoplasmic inclusions found in 
ALS and FTD patients28. Approximately 97% of FALS and SALS patients are positive for TDP-43 
inclusions in the motor cortex and spinal cord, thereby establishing TDP-43 as a major protein 
signature for disease, not just those carrying TARDBP mutations16,29. The loss of TDP-43 nuclear 
localization in ALS is well documented and resulting splicing deficits in ALS cellular and animal 
models as well as in patient samples have been reported26,30,31. In addition to a loss of nuclear 
function, a cytoplasmic gain of function may also contribute to neurodegeneration. A mouse 
model with a mutation in the NLS of human TARDBP, thereby limiting TDP-43 to the cytoplasm, 
showed increased expression of transcription related and chromatin assembly genes as well as 
histone 3’ UTR processing genes32. Importantly, these transcriptional changes were not seen 
when an antisense oligomer was added to knockdown TDP-43 expression, thereby supporting a 
cytoplasmic toxic gain of function. Finally, similar to the prion-like propagation of disease 
described in SOD-ALS, there is also evidence that wtTDP-43 oligomers can spread horizontally 
from cell to cell via microvesicles, including from ALS patient brain lysates, as well as vertically 
along axons33. Thus, reducing the aggregation of these mutant proteins is becoming a more 
widely applicable therapeutic strategy. 
 
ALS6: Fused in Sarcoma (FUS) 
 
The FUS gene on chr16p11.2 was first identified as a fusion oncogene in liposarcoma. FUS 
belongs to the FET protein family and has been shown to be an hnRNP due to its involvement in 
transcription process, transport, trafficking, alternative splicing and miRNA processing. Similar to 
TDP-43, it is also present in SGs. Structurally, FUS is comprised of 526 amino acids which form 
an N- terminal domain rich in glutamine-glycine-serine-tyrosine (QGSY), three arginine-glycine-
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glycine (RGG) rich domains, an RRM and a zinc finger motif as well as NES and NLS which 
enables nucleocytoplasmic shuttling of the protein34.  
 
Mutations in the FUS gene were initially identified in an AR Cape Verde family35, although 
subsequent screening established FUS to be causative also in AD ALS 35,36. FUS mutations 
account for about 4% FALS and 1% of SALS, with the majority of mutations located either within 
exons 3-6, encoding the QGSY-rich and first RGG region, or in exons 12-15, which encode zinc 
finger domain, the other 2 RGG domains and NLS34. Whilst these in the C-terminal have been 
shown to be functional, those in exons 3-6 are more commonly found in SALS or do not always 
segregate with disease, suggesting incomplete penetrance or non-pathogenic variations.  
 
Previously, depletion of RNA polymerase II (RNAP II) from the nucleus had been shown to lead 
to an increase of cytoplasmic FUS, suggesting FUS had a role in transcription37. It has 
subsequently been shown that FUS mediates the interaction between RNAP II and the splicing 
factor U1 snRNP, thereby coupling transcription to splicing38. Mutations in FUS lead to 
mislocalisation of both FUS and U1 snRNP to the cytoplasm39, and other RNA binding proteins, 
including SMN1, hnRNP A1 and A2 also co-localise in mtFUS aggregates40. The consequence of 
these mtFUS interactions includes dysregulated splicing and an increased binding of FUS with 
SMN, leading to a reduction in Gem bodies, thereby representing both a loss and gain of function 
by the mtFUS41.  
 
FUS mutations may also confer pathogenicity via additional interactions. FUS has been shown to 
bind mRNAs and facilitate their transport down dendrites42 and subsequently has been shown to 
bind to the polyA tail of AMPA receptor GluA1, regulating its stability, with the loss of FUS leading 
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to a reduction of GluA143. FUS has also been shown to translocate to the mitochondria through 
interaction with the mitochondrial chaperone heat shock protein 60 (HSP60) leading to 
mitochondrial damage44. Finally, mtFUS interacts with Pur-alpha in SGs and increases 
phosphorylation of the elongation initiation factor 2-alpha (eIF2-alpha), consequently inhibiting 
protein synthesis45. However, the contribution of each of these interactions on disease 
pathogenesis remains to be determined. 
 
FTD-ALS1: C9ORF72 (C9ORF72) 
 
The most common cause of FALS to date is the expansion of an intronic GGGGCC repeat in 
C9ORF72. The region was originally identified through genome wide association studies of SALS 
cases, as well as within the Finnish ALS population46,47; whilst initially sequencing of the gene 
failed to identify any point mutations, targeted NGSof the region established an intronic repeat 
region between the non-coding exons 1a and 1b48,49. Whilst healthy controls most commonly 
have less than 10 hexanucleotide repeats, individuals with ALS usually carry 400-2000 repeats. 
The repeat expansion has been identified in 37.6% of FALS and 6.3% of SALS, as well as in up 
to 25.1% of familial FTD cases50. Therefore, it is not surprising that the most significant clinical 
phenotype associated with this genetic subtype is an increased incidence of a family history of 
FTD. In addition, there is evidence that there are more bulbar-onset cases associated with 
C9ORF72-related ALS (up to 44%, compared to 25-26% in non-C9ORF72 ALS), with some 
studies also reporting an earlier age of onset (by 1.8-5.0yrs) and shorter disease duration (by 5.7-
12.0mths)51.  
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The function of the C9ORF72 gene is currently being determined, though structural analysis has 
established there is similarity to “differentially expressed in normal and neoplasic (DENN)-like 
proteins, which are GDP/GTP exchange factors regulating Rab-GTPases involved in vesicular 
trafficking52. Further work demonstrated how C9ORF72 colocalised with Rab proteins involved in 
autophagy and endosomal trafficking53. Whilst the function is being established, several 
hypotheses have been proposed to explain how the intronic hexanucleotide repeat may cause 
neurodegeneration: 1) Haploinsufficiency, 2) RNA toxicity and 3) Dipeptide repeat (DPR) protein 
toxicity.  
 
Haploinsufficiency: Lower levels of C9ORF72 transcript were seen in patients with the repeat 
expansion compared to controls and the haploinsufficiency hypothesis was supported when 
knockdown of the C9orf72 homolog in zebrafish caused an axonal degeneration54. In contrast, in 
a conditional C9orf72 knockout mouse, where C9orf72 was specifically ablated in neuronal cells, 
there was no evidence of a neurodegenerative phenotype55. However, a systematic investigation 
of the expression levels of the three C9ORF72 transcripts (variant 1 = exon 1a, 2-5; variant 2 = 
exon 1b, 2-11; variant 3 = exon 1a, 2-11) demonstrated significantly reduced expression of 
variants 1 and 2 in cerebellum and frontal cortex of C9ORF72 expansion carriers, with a 
correlation between a higher level of expression of variant 1 and survival56.This suggests that 
antisense oligomer strategies should avoid reducing C9ORF72 expression levels. 
 
RNA Toxicity: RNA foci were identified located primarily in the nucleus and occasionally in the 
cytoplasm of motor neurons and were found to be composed of both sense and antisense RNA57. 
The presence of antisense RNA foci have been shown to be correlated with TDP-43 
mislocalisation58, but not DPRs57. The repeat sequence is thought to form G-quadruplex 
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structures within the cell. Many RNA binding proteins co-localise with the RNA foci, potentially 
sequestering them from the cell and disrupting their RNA processing functions59,60. This may 
underlie the significant dysregulation of RNA splicing that is seen in the presence of the 
expansion, where greater disruption is present in patients with a shorter survival61,62. RNA foci 
have, however, been observed in fibroblasts from asymptomatic patients59,63 and in BAC 
transgenic mice containing an expanded allele, whilst RNA foci and DPRs recapitulate the 
neuropathology of ALS, there is no evidence of neurodegeneration64,65. This is in contrast to a 
mouse expressing a 66-repeat G4C2 expansion specifically in the CNS, which exhibited 
neuropathological, behavioural and motor deficits at 6mths66. 
 
DPR Proteins: Finally, it was demonstrated that the GGGGCC repeat expansion was subject to 
repeat-associated non-ATG (RAN) translation67. Both the sense and antisense RNA are 
translated, forming DPR proteins comprised of poly-GA, -GP, -GR, -PA and –PR (with poly-GP 
generated from both antisense and sense RNA)57,68. These DPR proteins are found aggregated 
within the neuronal cytoplasmic inclusions and neuronal intranuclear inclusions in the motor 
cortex, cerebellum, hippocampus and spinal cord, which also stain positive for ubiquitin and p62. 
Recently, antibodies raised against each of the DPR proteins have demonstrated that there is 
little correlation between DPR distribution/burden and clinical phenotype69,70, which the authors 
suggest is evidence against DPR aggregation being a major pathogenic mechanism. This is in 
contrast to work using a Drosophila model, in which DPR expression caused neurodegeneration 
in the fly eye71.  
 
In summary, there appears to be growing evidence supporting some form of RNA dysregulation 
as a contributing mechanism to C9ORF72-ALS. However, whilst different cellular and animal 
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models using different constructs are generating conflicting results on the contribution of each of 
the three hypotheses, the precise mechanism(s) still remain to be fully elucidated. Disruption of 
C9ORF72 protein function in endosomal trafficking may also be a contributory factor. 
 
OTHER RNA PROCESSING GENES ASSOCIATED WITH ALS 
 
Prior to the identification of TARDBP and FUS as ALS-associated genes, several RNA 
processing genes had been already been implicated in ALS: angiogenin (ANG) and senataxin 
(SETX). Subsequently, mutations in hnRNPA1 and matrin 3 (MATR3) have been identified 
through WES and ataxin 2 (ATXN2) was identified as a risk factor. 
 
ALS9: Angiogenin (ANG): Following the identification of the ANG single nucleotide 
polymorphism (SNP) rs11701 as over-represented in ALS cases from Scotland and Ireland, 
screening of ANG identified 7 missense mutations in 15 ALS cases, of which 4 were FALS 
(1.54%) and 11 were SALS (0.80%)72. ANG is a member of the pancreatic ribonuclease 
superfamily and is neuroprotective, whilst in mtANG this ability is impaired73. Whilst multiple 
mutations have been identified, p.K17I has not always shown disease segregation. However, a 
meta-analysis has demonstrated that Caucasian individuals carrying this allele have a 1.65 
greater risk of ALS, which is increased to 10-fold in FALS74. ANG has also been shown to induce 
the assembly of SGs75. Interestingly, this induction is inhibited by G-quadruplex structures, which 
are formed by the G4C2 C9ORF72 expanded repeat, thereby establishing a link between 
C9ORF72 and ANG. 
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ALS4: Senataxin (SETX): Mutations in SETX are associated with the juvenile onset of ALS with 
distal muscle weakness and absence of bulbar or sensory symptoms. Patients typically have a 
long and slow disease progression with a relatively normal life span76,77. Rare, AD mutations in 
SETX occur in ALS, while recessive SETX mutations are associated with ataxia-oculomotor 
apraxia-2 (AOA2)77. The mechanisms by which SETX variants lead to ALS is unknown; however, 
SETX encodes a DNA/RNA helicase protein proposed to play a role in DNA repair in response to 
oxidative stress. SETX also interacts with RNA processing proteins regulating transcription and 
pre-mRNA processing suggesting the cause of motor neuron degeneration through SETX 
mutations is as a result of abnormal RNA processing78. 
 
ALS13: Ataxin 2 (ATXN2): More than 36 repeats of CAG within ATXN2 causes spinocerebellar 
ataxia 2; however, intermediate repeats of 27-33 were found to strongly associate with ALS 
having established that ATXN2 modifies TDP-43 toxicity in yeast79. ATXN2 is an RNA binding 
protein that is involved in RNA processing and localised to the ER, Golgi apparatus and SGs; 
ATXN2 also interacts with FUS and intermediate expansions exacerbate the FUS mutant 
phenotype in cellular models80. A recent meta-analysis of over 6000 ALS and 7000 controls has 
identified that repeat lengths of 25-28 were actually protective, whereas the significant risk was 
associated with CAG repeats of 31-3381. This finding is supported by an Italian study, where 
additionally, <31 repeats were associated with spinal onset ALS and a shorter survival82.  
 
ALS20: Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1): Following the identification 
of hnRNPA1 and hnRNPA2B1 mutations as causative in multisystem proteinopathy families using 
exome sequencing, these genes were specifically analysed in 212 FALS for which exome 
sequencing was available83. A single case was identified with a mutation in hnRNPA1. 
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Interestingly, hnRNPA1 and A2/B1 are known interacting partners of TDP-43 and hnRNPA1 also 
interacts with ubiquilin-284. In ALS motor neurons, there is a loss of intense hnRNPA1 nuclear 
staining, which also correlates with nuclear loss of TDP-43, although hnRNPA1 was not seen to 
co-localise with TDP-43 in the skein-like inclusions85. However, screening of 113 Italian FALS as 
well as 135 Dutch FALS and 1084 Dutch SALS failed to find any hnRNPA1 mutations, suggesting 
this is a very rare cause of FALS. 
 
ALS21: Matrin 3 (MATR3): Exome sequencing of a large pedigree identified a mutation in the 
MATR3 gene; a previous family carrying a mutation in MATR3, originally diagnosed with AD 
distal, asymmetrical myopathy with vocal cord paralysis were re-assessed and re-diagnosed as 
having ALS86. Further screening of Italian and British ALS cases identified a further 2 mutations; 
one FALS and one SALS. MATR3 is an RNA/DNA binding protein that interacts with TDP-43; 
whilst the p.S85C mutation enhances this interaction, two other mutations, p.F115C and p.T22A, 
do not. However, this difference may underlie the slow progression of the disease in the family 
carrying the p.S85C mutation. Whilst no further mutations were found in 372 FALS cases from 
France, Taiwan, Australia and French Canada, 4 mutations were found in apparent SALS cases 
(3 in French-Canadians and in 1 Taiwanese)87-90. 
 
FET Family Genes: The TATA box-binding protein-associated factor 15 (TAF15) and Ewing 
sarcoma breakpoint region 1 (EWSR1) are RNA binding proteins and form the FET family of 
proteins along with FUS. All three contain prion-like domains, a feature used to rank potential 
RNA binding proteins as being involved in ALS following a functional yeast screen91. Screening of 
TAF15 identified 5 missense variants in 1262 ALS cases, whilst screening EWSR1 identified 2 
potential mutations among 817 ALS cases92. Whilst these variants were absent from controls, 
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they were identified in SALS patients, so segregation could not be demonstrated. However, both 
TAF15 and EWSR1 proteins show cytoplasmic mislocalisation in SALS. Recently, whole genome 
sequencing identified an EWSR1 mutation in a set of monozygote twins disconcordant for ALS, 
suggesting additional factors may influence disease93. 
 
PROTEIN TRAFFICKING AND DEGRADATION RELATED GENES 
 
From the identification of the first gene for AR ALS, ALS2, combined with the presence of 
characteristic ubiquitinated inclusions in ALS motor neurons, dysregulation of protein trafficking 
and protein degradation have been implicated in the disease process. Mutations in genes 
involved in endosomal transport include alsin (ALS2), vesicle associated membrane protein 
[VAMP] associated protein B (VAPB), chromatin modifying protein 2B (CHMP2B) and 
phosphoinositide 5-phosphatase (FIG4), those involved in the UPS include ubiquilin 2 (UBQLN2), 
sequestosome 1 (SQSTM1) and sigma non-opioid intracellular receptor 1 (SIGMAR1) and 
autophagy is primarily implicated by mutations in optineurin (OPTN), valosin containing protein 
(VCP) and tank-binding kinase 1 (TBK1). There is some overlap between these three biological 
pathways, which have also been implicated in SOD1 and C9ORF72-related ALS. 
 
ALS2: Alsin (ALS2): The ALS2 gene was originally identified through linkage analysis in 
consanguineous families from Tunisia and Saudi Arabia94,95. The majority of the mutations lead to 
protein truncations, leading to a proposed loss of function. Alsin is thought to play a role activating 
Rab5 GTPases. Rab5 is essential for endosomal trafficking and in alsin knockout mice, neurons 
showed increased endosomal fusion and degradation but reduced mobility96. One of the 
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endosome components is the AMPA receptor GluR2, levels of which are reduced in alsin 
knockout mice97.  
 
ALS8: Vesicle associated membrane protein [VAMP] associated protein B (VAPB): Linkage 
analysis of a large Brazilian family first established VAPB as a causative gene for ALS 98 and the 
p.P56S mutation has been identified in multiple Brazillian pedigrees, indicative of a common 
founder 99. Additional mutations have been reported, though not all of the variations found 
segregated with disease100-103. VAPB is a type II integral ER membrane protein, involved in 
intracellular trafficking and the unfolded protein response (UPR)104 as well as regulating ER- 
mitochondria interactions105. However, the p.P56S mutant protein is unable to initiate the UPR, 
altered calcium uptake into the mitochondria and disrupted anterograde axonal transport of 
mitochondria106-108. 
  
ALS17: Chromatin modifying protein 2B (CHMP2B): Mutations in CHMP2B were initially 
identified in two probable FALS and a further 3 SALS cases; the majority had a predominant 
lower motor neuron phenotype109,110. CHMP2B is a component of the ESCRT-III endosomal 
trafficking system, sorting cargos into multivesicular bodies (MVBs). More recently 4 novel 
mutations were identified in apparently sporadic ALS cases, and these were located in the 
domain required to form the MVBs2. In cellular models, mutant CHMP2B led to the formation of 
large vacuoles, and an increase in autophagy marker LC3-II, implicating dysregulation of 
autophagy as a mechanism in ALS. 
 
ALS11: Phosphoinositide 5-phosphatase (FIG4): Mutations in FIG4 were originally identified 
as causative in Charcot-Marie-Tooth disease type 4J, though one family had a clinical phenotype 
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resembling ALS. Screening of FALS and SALS cases identified 9 variants, with 6 showing 
impaired function in yeast111. FIG4, also known as SAC3, regulates PI(3,5)P2 levels, and thereby 
controls retrograde trafficking of endosomal vesicles to the Golgi. The mutant proteins showed 
loss of phosphatase activity, mislocalisation and inability to bind to the PI(3,5)P2 complex. Further 
screening in Italian and Taiwanese populations failed to find any novel variants, though only 80 
SALS and 15 FALS were screened in each study112,113. No pathological assessment was 
available on the mutation carriers, however, FIG4 was not shown to be mislocalized in SALS114. 
 
ALS15: Ubiquilin 2 (UBQLN2): UBQLN2 was identified by linkage analysis in a large 
multigenerational family. Screening of additional FALS cases with no male to male transmission 
found 4 further mutations; these were all located within the PXX repeat region of the protein115. 
Additional screening identified further variants adjacent or within the PXX repeat region116,117. 
Mutations have been shown to disrupt the protein degradation pathway through defective binding 
to the proteasome118 and causing mislocalisation of OPTN from Rab-11 positive endosomal 
vesicles119, as well as potentially impairing RNA metabolism, through loss of binding of UBQLN2 
to hnRNP proteins, including hnRNPA184. 
 
FTDALS3: Sequestosome 1 (SQSTM1): SQSTM1 or p62 is a ubiquitin binding protein that plays 
a role in protein degradation via the proteasome and autophagy, and is found within the 
characteristic ubiquitinated inclusions in ALS patients. Screening of this gene found multiple 
mutations in both FALS and SALS cases120. Further mutations were found in ALS patients, some 
in association with Paget disease of bone, which is also known to be caused by SQSTM1 
mutations121,122. In a zebrafish model, where endogenous SQSTM1 was knocked-down, the fish 
showed behavioural and axonal abnormalities, as well as disrupted autophagy, as demonstrated 
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by increased mTOR levels123. Human SQSTM1 was able to rescue the phenotype, but the 
frequently found mutation, p.P392L, was unable to do so. 
 
ALS16: Sigma non-opoid intracellular receptor 1 (SIGMAR1):  Initially 3’UTR variants were 
identified within several AD FTD-ALS or FTD families and suggested pathogenicity occurred 
through alteration of mRNA stability124. However, using homozygosity mapping, a missense 
mutation in SIGMAR1 was subsequently found to segregate in a large consanguineous family 
with AR juvenile ALS125. SIGMAR1 is an ER chaperone, a subunit of the ligand-regulated 
potassium channel and enables mitochondrial calcium transport via the IP3 receptor; mutation of 
SIGMAR1 causes the formation of cytoplasmic aggregations, a reduction in ATP production and 
subsequent decrease in proteasome activity126. However, whether SIGMAR1 contributes to AD 
ALS is yet to be fully elucidated. 
 
ALS12: Optineurin (OPTN): Mutations in OPTN were originally identified through homozygosity 
mapping of consanguineous Japanese AR ALS families, which identified a homozygous exonic 
deletion and a homozygous nonsense mutation127. Further screening of FALS cases identified 
two AD families heterozygous for a missense mutation. OPTN mediates it’s function through 
protein-protein interactions; it binds to ubiquitin and UBQLN2, is an autophagy receptor 
(facilitating the recruitment of cargos to autophagosomes), is required for Golgi organisation (as 
demonstrated by the Golgi fragmentation seen in post-mortem spinal motor neurons128) and also 
regulates NFkB signalling129. Subsequent screening has identified additional heterozygote 
mutations, including in SALS cases130, as well as in AR ALS cases131,132. 
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ALS14: Valosin containing protein (VCP): Exome sequencing of a four-generation Italian 
family initially suggested mutation of VCP as causative in ALS133. Subsequently, a further 4 
variants were identified in FALS cases, thereby providing further evidence that VCP is associated 
with ALS. VCP is an AAA+-ATPase involved in a variety of cellular functions including mediating 
the proteasomal degradation of ubiquitinated protein in multimeric complexes and the targeting of 
substrates to autophagosomes134. Whilst screening failed to find any VCP mutations in some 
populations135-137, potential mutations were found in others and also in SALS cases138,139. VCP 
mutations are also associated with IBMPFD and patient fibroblasts have shown mitochondrial 
uncoupling and a reduction in ATP production140, a feature also seen with SIGMAR1 mutations. 
 
FTDALS4: TANK-binding kinase (TBK1): Mutations in TBK1 were initially identified through 
exome sequencing 2874 ALS cases; dominant variants were found in 1.097% of cases and loss 
of function mutations in 0.382%141. This was shortly followed by a second paper in which 
sequencing of 252 FALS cases identified 9 loss of function and 4 missense mutations142. 
Mutations have subsequently been found in both ALS, FTD-ALS and FTD cases143,144. TBK1 has 
a role in both innate immunity, NFkB signalling, as well as in autophagy. TBK1 binds and 
phosphorylates ALS-related proteins OPTN and SQSTM1, whereas TBK1 mutants have been 
shown to no longer bind OPTN142. 
 
IMPAIRED AXONAL TRANSPORT AND CYTOSKELETAL DYSFUNCTION 
 
Neurons are extremely large cells which require transport of organelles, proteins and RNA from 
the cell body down the axons.  Molecular motors such as kinesins and dynein guide these cargos 
to microtubules to mediate anterograde and retrograde transport, respectively. Whilst mutation of 
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the p150 dynactin subunit in mice generated a neurodegenerative phenotype, mutations in this 
gene were not found in human ALS145,146. However, exome sequencing has identified several 
cytoskeletal genes with mutations reported to be causative in ALS. 
 
ALS5: Spatacsin (SPG11): WES of two affected siblings from a non-consanguineous family 
diagnosed with autosomal recessive juvenile onset ALS (ARJALS) identified only one gene, 
SPG11, in which variants were found in a compound heterozygous state147. The involvement of 
the hereditary spastic paraparesis gene, normally associated with HSP with thin corpus callosum, 
had previously been implicated by a candidate gene screening of SPG11, in which mutations in 
10 families with ARJALS were identified148. Whilst the exact function of the protein is unknown, 
iPSC-derived neuronal cells with SPG11 mutations demonstrated the protein co-localised with the 
cytoskeleton, and mutations caused axonal instability and impaired axonal transport149.  
 
ALS18: Profilin 1 (PFN1): Two multi-generational ALS families were determined to carry 
mutations in the PFN1 gene following WES150. Extending the screen to additional FALS cases, 
identified a further 3 mutations in 5 FALS cases as well as a p.E117G variant, that was identified 
at very low frequency in controls. Further screening of ALS cases identified additional mutations 
as well as the variant151-154. A meta-analysis subsequently determined that the p.E117G was 
associated with ALS and proposed this variant as a risk factor155. The function of PFN1 is to 
convert monomeric actin to filamentous actin and it is also found localised to SGs156. It has been 
demonstrated that PFN1 mutations destabilise the protein, thereby leading to a loss of function, 
whilst the mutant protein is misfolded, thereby leading to a gain of function through aberrant 
protein interactions157. However, the effect of the mutant protein on actin formation and SG 
dynamics is yet to be elucidated.  
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ALS22: Tubulin alpha 4A (TUBA4A): WES of 363 FALS index cases followed by rare variant 
burden identified 5 ALS cases with rare variants in TUBA4A; these included 4 missense 
mutations and 1 nonsense mutation, all of which were encoded in exon 4, in highly conserved 
amino acids, and absent from 4300 EVS controls158. Whilst further sequencing of ALS cases only 
identified one further variant, functional studies demonstrated that the p.W407X nonsense mutant 
failed to localise to the microtubules, instead forming cytoplasmic inclusions, leading to disrupted 
microtubule assembly and stability, through a dominant-negative mechanism. Subsequent 
screening in the Chinese ALS population, failed to identify any variants159; data from other 
populations will undoubtedly emerge as further WES experiments are completed.  
 
Intermediate Filament Variants: Cytoskeletal dysfunction is further implicated in the 
pathogenesis of ALS through rare variants being identified in intermediate filament genes. 
Neurofilaments (light, medium and heavy) are major structural components of the neuronal 
cytoskeleton and are present within the characteristic ubiquitinated protein inclusions. Candidate 
gene screening identified rare insertion/deletion variants in the KSP repeat domains of 
neurofilament heavy (NEFH) gene in SALS cases160-162, whilst a single frameshift mutation has 
been identified in peripherin (PRPH1)163. However, the absence of mutations in known familial 
cases and ability to show segregation with disease has reduced the creditability of these genes 
as ALS loci. 
 
ADDITIONAL LOCI 
 
23 
 
Several additional ALS loci have been identified. Two loci are yet to have their associated genes 
identified: ALS3 on chr18q21 and ALS7 on chr20q13164,165. A further two genes have been 
identified in FALS pedigrees, though their functional effects are currently predicted to disrupt 
neuronal development and mitochondrial function. 
 
ALS19: Erb-b2 receptor tyrosine kinase 4 (ERBB4): Whole genome sequencing (WGS) of a 
Japanese AD ALS family identified a missense mutation in ERBB4166. Additional screening 
identified the same mutation in an unrelated Canadian family and a further mutation in a SALS 
case. ERBB4 is a receptor tyrosine kinase which is activated by neuregulin, resulting in 
autophosphorylation of the C-terminal. Mutations in ERBB4 reduced the level of 
autophosphorylation. ERBB4 was found to localise to C-boutons, arising from interneurons, which 
synapse with spinal motor neurons167. Interestingly, C-boutons are not found in oculomotor 
neurons, which are spared in ALS, whilst increases in neuregulin levels in C-boutons increase 
during disease progression of the SOD1 G93A transgenic mice.  
 
FTDALS2: Coiled-coil helix coiled-coil helix domain containing protein 10 (CHCHD10): 
CHCHD10 was initially associated with ALS through WES of a family exhibiting clinical features 
including ALS, FTD, cerebellar ataxia and myopathy168. This led to ALS and ALS-FTD families 
being screened. Several additional mutations were found169,170, though it became evident that the 
p.P34S mutation was non-pathogenic, as it was also found at similar frequencies in controls171. 
The function of CHCHD10 is unknown, it localises to the mitochondria. Fibroblasts from family 
members of the original pedigree showed multiple mitochondrial DNA deletions, respiratory chain 
defects and structurally abnormal mitochondria, suggesting CHCHD10 may have a role in the 
respiratory chain and/or in mitochondrial genome stability168. This has been supported by 
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additional work by Genin and colleagues, which not only found loss of cristae and mitochondrial 
genome repair in patient fibroblasts, but a failure of apoptosis, due to an inability to release 
cytochrome C172.  
 
CONCLUSION 
 
ALS genetics is having a significant impact on our understanding of the disease and the 
mechanisms implicated in neurodegeneration. The majority of genes encode proteins involved in 
RNA processing and the protein degradation pathways, UPS and autophagy. However, neither of 
these or the other pathways implicated work in isolation, but impact on other cellular processes. 
The proposed mechanisms are mutually compatible and it is most likely that multiple 
dysregulated pathways contribute to the loss of motor neurons. This is clearly demonstrated by 
TDP-43, an RNA binding protein which is mislocalised from the nucleus, thereby causing loss of 
nuclear function, and which is the aggregated in the cytoplasm as a component of the 
characteristic ubiquitinated inclusions.   
 
Along with multiple genetic causes, it is clear that these genes are also implicated in additional 
disorders, not only other neurodegenerative disorders such as FTD, HSP and ataxia, but also 
myopathies, Paget disease of bone and glaucoma (Table 2). The use of WES or WGS, in 
projects such as the 100,000 Genomes Project in the UK (www.genomicsengland.co.uk), or 
Project Mine among the International ALS community (www.projectmine.com), will potentially 
enable a greater understanding of why mutations in a gene in one family present with a specific 
clinical phenotype, whilst another family shows a different disease.  
 
25 
 
WES and WGS will also further our understanding of the impact of oligogenic inheritance in ALS. 
Whilst family pedigrees clearly show inheritance in an AD manner for classical ALS, the move 
away from analysing a single gene at a time has highlighted evidence of mutations in multiple 
ALS genes in some patients2. Screening of a large ALS cohort demonstrated that 14% of FALS 
and 2.6% of SALS cases had more than one potential pathogenic mutation in a known ALS gene, 
and these cases had a significantly earlier onset of disease173. This also highlights the fact that 
apparent SALS cases also carry genetic mutations, as has been evidenced by the identification of 
de novo mutations in SALS cases following WES of case and unaffected parents trios174,175. 
Whilst in some cases, these may actually be rare AR mutations, additional WES and WGS 
sequencing of cases will allow the genetic contribution in SALS, estimated to be 61%176, to be 
elucidated. 
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FIGURE LEGEND 
 
Figure 1: Gene Frequencies in ALS. Each gene is plotted against the year it was found; size of 
circles signifies the frequency of mutations in FALS (ALS) as listed on Table 1. Where gene 
frequencies were not available, for illustrative purposes, these have been given circle size 
equivalent to 1%. 
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